Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy

78Citations
Citations of this article
83Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Cancer dormancy is a poorly understood stage of cancer progression. However, the ability to control this step of the disease offers novel therapeutic opportunities. Here we summarize recent findings that implicate the extracellular matrix and adhesion receptor signaling in the escape or induction of tumor dormancy. We further review evidence suggesting that imbalances in the activity ratio of ERK to p38 signaling may determine the fate (i.e., tumorigenicity vs. dormancy) of different carcinoma cells. Special attention is placed on the mechanisms that p38 signaling regulates during the induction of dormancy and how modulation of these pathways may offer a therapeutic opportunity. We also review evidence for a novel drug-resistance mechanism in dormant tumor cells that when blocked may enable killing of dormant tumor cells. Finally, we explore the notion that dormancy of tumor cells may be the result of a selective adaptive response that allows disseminated tumor cells to pause their growth and cope with stress signaling imposed by dissemination and/or treatment until growth can be restored. ©2006 Landes Bioscience.

Cite

CITATION STYLE

APA

Ranganathan, A. C., Adam, A. P., & Aguirre-Ghiso, J. A. (2006, August 15). Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle. Taylor and Francis Inc. https://doi.org/10.4161/cc.5.16.3109

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free